Activin and Inhibin

Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor . Dagrocorat hydrochloride is also a time-dependent reversible inhibitor of CYP3A ( IC 50 =1.3 μM in human liver

Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor . Dagrocorat hydrochloride is also a time-dependent reversible inhibitor of CYP3A ( IC 50 =1.3 μM in human liver

Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes

Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes

Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal

Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal

Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC 50 values of 12.4 nM and 9.9 nM, respectively. Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal

DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.In VitroDAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival,

DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.In VitroDAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival,

DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.In VitroDAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival,

DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.In VitroDAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival,

DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.In VitroDAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival,